Have a feature idea you'd love to see implemented? Let us know!

HRTX Heron Therapeutics Inc

Price (delayed)

$1.82

Market cap

$276.04M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.3

Enterprise value

$436.36M

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs. Heron ...

Highlights
Heron Therapeutics's EPS has surged by 73% YoY and by 49% QoQ
HRTX's gross profit has surged by 67% year-on-year and by 18% since the previous quarter
The quick ratio has grown by 39% YoY but it has contracted by 3.3% from the previous quarter
The equity has declined by 12% since the previous quarter but it is up by 3.4% year-on-year
The debt is up by 14% year-on-year

Key stats

What are the main financial stats of HRTX
Market
Shares outstanding
151.67M
Market cap
$276.04M
Enterprise value
$436.36M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Earnings
Revenue
$136.36M
EBIT
-$47.62M
EBITDA
-$44.85M
Free cash flow
-$22.51M
Per share
EPS
-$0.3
Free cash flow per share
-$0.15
Book value per share
-$0.25
Revenue per share
$0.9
TBVPS
$1.43
Balance sheet
Total assets
$218.14M
Total liabilities
$256.08M
Debt
$178.71M
Equity
-$37.94M
Working capital
$110.85M
Liquidity
Debt to equity
-4.71
Current ratio
2.38
Quick ratio
1.76
Net debt/EBITDA
-3.57
Margins
EBITDA margin
-32.9%
Gross margin
65.5%
Net margin
-35.3%
Operating margin
-34%
Efficiency
Return on assets
-21.7%
Return on equity
N/A
Return on invested capital
-16%
Return on capital employed
-34.6%
Return on sales
-34.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HRTX stock price

How has the Heron Therapeutics stock price performed over time
Intraday
-2.15%
1 week
-12.08%
1 month
0%
1 year
100.88%
YTD
7.06%
QTD
-8.54%

Financial performance

How have Heron Therapeutics's revenue and profit performed over time
Revenue
$136.36M
Gross profit
$89.31M
Operating income
-$46.39M
Net income
-$48.13M
Gross margin
65.5%
Net margin
-35.3%
HRTX's operating margin has surged by 71% year-on-year and by 45% since the previous quarter
The net margin has soared by 70% year-on-year and by 42% since the previous quarter
HRTX's gross profit has surged by 67% year-on-year and by 18% since the previous quarter
The operating income has surged by 66% year-on-year and by 44% since the previous quarter

Growth

What is Heron Therapeutics's growth rate over time

Valuation

What is Heron Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.2
Heron Therapeutics's EPS has surged by 73% YoY and by 49% QoQ
The equity has declined by 12% since the previous quarter but it is up by 3.4% year-on-year
HRTX's price to sales (P/S) is 75% less than its 5-year quarterly average of 8.2 and 19% less than its last 4 quarters average of 2.5
HRTX's revenue is up by 16% year-on-year and by 3.2% since the previous quarter

Efficiency

How efficient is Heron Therapeutics business performance
Heron Therapeutics's return on sales has surged by 70% YoY and by 43% QoQ
The ROIC has soared by 67% YoY and by 43% from the previous quarter
HRTX's ROA has soared by 62% YoY and by 42% QoQ

Dividends

What is HRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HRTX.

Financial health

How did Heron Therapeutics financials performed over time
Heron Therapeutics's total assets is 15% lower than its total liabilities
The quick ratio has grown by 39% YoY but it has contracted by 3.3% from the previous quarter
The current ratio has grown by 25% YoY but it has contracted by 3.6% from the previous quarter
The debt to equity has declined by 19% year-on-year but it is up by 11% since the previous quarter
The debt is up by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.